- Home
- EWCZ vs CYBN Comparison
EWCZ vs CYBN Comparison
Compare EWCZ & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- CYBN
- Stock Information
- Founded
- EWCZ 2004
- CYBN 2019
- Country
- EWCZ United States
- CYBN Canada
- Employees
- EWCZ N/A
- CYBN N/A
- Industry
- EWCZ Package Goods/Cosmetics
- CYBN Pharmaceuticals and Biotechnology
- Sector
- EWCZ Consumer Discretionary
- CYBN Health Care
- Exchange
- EWCZ Nasdaq
- CYBN Nasdaq
- Market Cap
- EWCZ 166.5M
- CYBN 147.4M
- IPO Year
- EWCZ 2021
- CYBN N/A
- Fundamental
- Price
- EWCZ $3.72
- CYBN $5.87
- Analyst Decision
- EWCZ Hold
- CYBN Strong Buy
- Analyst Count
- EWCZ 6
- CYBN 3
- Target Price
- EWCZ $5.50
- CYBN $85.00
- AVG Volume (30 Days)
- EWCZ 297.3K
- CYBN 1.1M
- Earning Date
- EWCZ 11-12-2025
- CYBN 11-17-2025
- Dividend Yield
- EWCZ N/A
- CYBN N/A
- EPS Growth
- EWCZ N/A
- CYBN N/A
- EPS
- EWCZ 0.20
- CYBN N/A
- Revenue
- EWCZ $212,509,000.00
- CYBN N/A
- Revenue This Year
- EWCZ N/A
- CYBN N/A
- Revenue Next Year
- EWCZ $2.27
- CYBN N/A
- P/E Ratio
- EWCZ $18.95
- CYBN N/A
- Revenue Growth
- EWCZ N/A
- CYBN N/A
- 52 Week Low
- EWCZ $2.72
- CYBN $4.81
- 52 Week High
- EWCZ $8.91
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- EWCZ 49.19
- CYBN 42.32
- Support Level
- EWCZ $3.47
- CYBN $6.86
- Resistance Level
- EWCZ $3.91
- CYBN $8.00
- Average True Range (ATR)
- EWCZ 0.16
- CYBN 0.48
- MACD
- EWCZ 0.04
- CYBN -0.06
- Stochastic Oscillator
- EWCZ 56.84
- CYBN 6.99
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.